The content is available as a PDF (933.7 KB).
. 2022 Jun 16;162(7):S-278. doi: 10.1016/S0016-5085(22)60657-7
1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
Judith Wellens
, Matthew Edmans
, Uri Obolski
, Luke Marlow
, Stephanie Brann
, Susanna Dunachie
, David W Eyre
, Drew Helmus
, Eleanor Barnes
, Jean Frederic Colombel
, Serre-Yu Wong
, Paul Klenerman
, James O Lindsay
, Craig Thompson
, Jack J Satsangi
Judith Wellens
Find articles by Judith Wellens
Matthew Edmans
Find articles by Matthew Edmans
Uri Obolski
Find articles by Uri Obolski
Luke Marlow
Find articles by Luke Marlow
Stephanie Brann
Find articles by Stephanie Brann
Susanna Dunachie
Find articles by Susanna Dunachie
David W Eyre
Find articles by David W Eyre
Drew Helmus
Find articles by Drew Helmus
Eleanor Barnes
Find articles by Eleanor Barnes
Jean Frederic Colombel
Find articles by Jean Frederic Colombel
Serre-Yu Wong
Find articles by Serre-Yu Wong
Paul Klenerman
Find articles by Paul Klenerman
James O Lindsay
Find articles by James O Lindsay
Craig Thompson
Find articles by Craig Thompson
Jack J Satsangi
Find articles by Jack J Satsangi
Issue date 2022 May.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9212638